Results 41 to 50 of about 1,610,894 (277)

Increased co-expression of TIM-3 with TIGIT or 2B4 on CD8+ T cells is associated with poor prognosis in locally advanced nasopharyngeal carcinoma

open access: yesBiomolecules & Biomedicine, 2023
The use of immune checkpoint inhibitors in malignant tumors improves patient outcomes. Because single-agent immune checkpoint blockade has a low objective response rate, it is meaningful to explore combined blockade of immune checkpoint receptors.
Xiaolin Xie   +6 more
doaj   +1 more source

Potential role for checkpoint blockade in combination immunotherapy for a functional cure.

open access: yes, 2019
A therapeutic vaccine (1) would enhance HIV-specific CTL number and function. Because many HIV-specific CTLs are exhausted during HIV, IC blockade could enhance the activating effect of the vaccine and the function of the CTL after activation.
Colin G. Graydon (6239621)   +5 more
core   +1 more source

Immune-Checkpoint Blockade Therapy in Lymphoma

open access: yes, 2020
Tumor cells use immune-checkpoint pathways to evade the host immune system and suppress immune cell function. These cells express programmed cell-death protein 1 ligand 1 (PD-L1)/PD-L2, which bind to the programmed cell-death protein 1 (PD-1) present on ...
Yosuke Minami   +3 more
core   +1 more source

Optimization of Immune Checkpoint Blockade via a Multiscale Model System

open access: yesComputational and Systems Oncology
Cancer progresses when cancer cells selectively bind to inhibitory receptors on a T cell surface, downregulating tumor immune response. One standard‐of‐care strategy to combat this process is immune checkpoint blockade.
Anne M. Talkington, Anthony J. Kearsley
doaj   +1 more source

Simultaneous inhibition of CXCR1/2, TGF-β, and PD-L1 remodels the tumor and its microenvironment to drive antitumor immunity

open access: yesJournal for ImmunoTherapy of Cancer, 2020
Background Despite the success of immune checkpoint blockade therapy in the treatment of certain cancer types, only a small percentage of patients with solid malignancies achieve a durable response.
Jeffrey Schlom   +11 more
doaj   +1 more source

Supplementary Figure from Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy

open access: yes, 2022
Supplementary Figure from Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade ...
Takahiro Karasaki (15120637)   +16 more
core   +1 more source

Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation

open access: yesFEBS Letters, EarlyView.
Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang   +2 more
wiley   +1 more source

Checkpoint Blockade in Combination with CD33 Chimeric Antigen Receptor T Cell Therapy and Hypomethylating Agent Against Acute Myeloid Leukemia

open access: yesBlood, 2019
Acute myeloid leukemia (AML) is the most common acute leukemia in adults. The cure rate for primary AML patients is only 35% and decreases with age. Novel and effective immunotherapies for patients with relapsed and/or refractory (r/r) AML remain an urgent unmet need.
Tongyuan Xue   +7 more
openaire   +1 more source

Ligand‐dependent transcriptional heterogeneity in cell cycle gene expression delays G1/S entry

open access: yesFEBS Letters, EarlyView.
EGF and HRG induce distinct G1/S progression programs in ErbB2‐amplified BT474 breast cancer cells. Despite activating the potent ErbB2–ErbB3 heterodimer, HRG does not accelerate cell‐cycle entry. Instead, EGF promotes earlier restriction‐point passage via ERK–FOS signaling, whereas HRG activates the AKT–MYC axis, driving transcriptional heterogeneity ...
Ririn Rahmala Febri   +5 more
wiley   +1 more source

Supplementary Table from Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade Therapy

open access: yes, 2022
Supplementary Table from Dietary Lactobacillus-Derived Exopolysaccharide Enhances Immune-Checkpoint Blockade ...
Takahiro Karasaki (15120637)   +16 more
core   +1 more source

Home - About - Disclaimer - Privacy